This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars. That’s when we’ll get the first look at data from a pivotal clinical trial of anito-cel, the personalized, BCMA-directed CAR-T therapy for multiple myeloma being developed under a partnership with Arcellx.
Anito-cel has multibillion-dollar sales potential, if it proves to be competitive on efficacy and safer from a neurotoxicity perspective than Carvykti, the currently approved BCMA CAR-T product from Johnson & Johnson and Legend Biotech. Carvykti is already on a billion-dollar run rate, with a peak sales forecast in the $5-6 billion range, according to Visible Alpha.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in